NCT04263454View on ClinicalTrials.gov

The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

December 22, 2021

Study Completion Date

December 22, 2021

Conditions
Fibromyalgia
Interventions
DRUG

Endotoxin, Escherichia Coli

Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.

PROCEDURE

Magnetic Resonance Spectroscopy

MRI is a non-invasive imaging technique and does not utilize ionizing radiation.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

American Fibromyalgia Syndrome Association

OTHER

lead

University of Alabama at Birmingham

OTHER

NCT04263454 - The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia | Biotech Hunter | Biotech Hunter